Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says Public drug plans should not cover lecanemab, a drug to slow early-stage Alzheimer's disease, Canada's Drug Agency says in its draft recommendation. February 19, 2026 Labels: CBC | Health News health Share to: Twitter Facebook URL Print Email
Post a Comment